South Korea · Delayed Price · Currency is KRW KOREA PHARMA Statistics
Total Valuation
KOREA PHARMA has a market cap or net worth of KRW 82.24 billion. The enterprise value is 87.79 billion.
| Market Cap | 82.24B |
| Enterprise Value | 87.79B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 2.13% in one year.
| Current Share Class | 10.91M |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | +2.13% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 63.38% |
| Owned by Institutions (%) | 0.01% |
| Float | 3.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.88 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | 10.67 |
| P/OCF Ratio | 9.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.52, with an EV/FCF ratio of 11.39.
| EV / Earnings | n/a |
| EV / Sales | 0.93 |
| EV / EBITDA | 20.52 |
| EV / EBIT | 73.18 |
| EV / FCF | 11.39 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.58 |
| Quick Ratio | 1.06 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 7.17 |
| Debt / FCF | 4.41 |
| Interest Coverage | 0.45 |
Financial Efficiency
Return on equity (ROE) is -1.07% and return on invested capital (ROIC) is 2.11%.
| Return on Equity (ROE) | -1.07% |
| Return on Assets (ROA) | 0.81% |
| Return on Invested Capital (ROIC) | 2.11% |
| Return on Capital Employed (ROCE) | 1.92% |
| Weighted Average Cost of Capital (WACC) | 8.24% |
| Revenue Per Employee | 701.02M |
| Profits Per Employee | -5.77M |
| Employee Count | 134 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.74 |
Taxes
| Income Tax | -1.19B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.09% in the last 52 weeks. The beta is 0.70, so KOREA PHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -44.09% |
| 50-Day Moving Average | 7,891.20 |
| 200-Day Moving Average | 11,124.95 |
| Relative Strength Index (RSI) | 51.56 |
| Average Volume (20 Days) | 12,444 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KOREA PHARMA had revenue of KRW 93.94 billion and -773.54 million in losses. Loss per share was -70.23.
| Revenue | 93.94B |
| Gross Profit | 33.64B |
| Operating Income | 1.67B |
| Pretax Income | -1.96B |
| Net Income | -773.54M |
| EBITDA | 4.75B |
| EBIT | 1.67B |
| Loss Per Share | -70.23 |
Balance Sheet
The company has 28.48 billion in cash and 34.03 billion in debt, with a net cash position of -5.55 billion or -508.95 per share.
| Cash & Cash Equivalents | 28.48B |
| Total Debt | 34.03B |
| Net Cash | -5.55B |
| Net Cash Per Share | -508.95 |
| Equity (Book Value) | 73.62B |
| Book Value Per Share | 6,731.64 |
| Working Capital | 25.25B |
Cash Flow
In the last 12 months, operating cash flow was 8.37 billion and capital expenditures -664.31 million, giving a free cash flow of 7.71 billion.
| Operating Cash Flow | 8.37B |
| Capital Expenditures | -664.31M |
| Depreciation & Amortization | 3.08B |
| Net Borrowing | -3.69B |
| Free Cash Flow | 7.71B |
| FCF Per Share | 706.85 |
Margins
Gross margin is 35.81%, with operating and profit margins of 1.78% and -0.82%.
| Gross Margin | 35.81% |
| Operating Margin | 1.78% |
| Pretax Margin | -2.09% |
| Profit Margin | -0.82% |
| EBITDA Margin | 5.06% |
| EBIT Margin | 1.78% |
| FCF Margin | 8.21% |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.66%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.66% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.13% |
| Shareholder Yield | -1.47% |
| Earnings Yield | -0.94% |
| FCF Yield | 9.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KOREA PHARMA has an Altman Z-Score of 2.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 5 |